ZOLL to display resuscitation technology, temperature management solutions at AHA 2011

ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that 27 scientific presentations related to ZOLL products and technology are scheduled to be presented during the American Heart Association (AHA) 2011 Resuscitation Science Symposium (ReSS) and Scientific Sessions. In addition, ZOLL will display its fully-integrated portfolio of resuscitation technology and temperature management solutions that address each link in the Chain of Survival in Booth #1035 at AHA November 13-15 in Orlando.

Two key AHA presentations involve ZOLL's AutoPulse® Non-invasive Cardiac Support Pump and the LifeVest® Wearable Defibrillator:

  • Lars Wik, M.D., Ph.D., Oslo University Hospital, Oslo, Norway, and Principal Investigator of the CIRC Trial, will present "Comparison of Survival to Hospital Discharge between Integrated AutoPulse-CPR and Manual-CPR during Out-of-Hospital Cardiac Arrest of Presumed Cardiac Origin: The Circulation Improving Resuscitation Care (CIRC) Trial" on Sunday, Nov. 13 at 8:00 a.m. in Room W415, Valencia Ballroom.
  • Edwin T. Zishiri, M.D., Cleveland Clinic, will present "Use of the Wearable Cardioverter Defibrillator and Survival After Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction," Monday, Nov. 14 at 3:45 p.m. in Room W204.

Additional presentations covering the AutoPulse and the LifeVest, as well as other ZOLL technology, including Real CPR Help®, See-Thru CPR®, and therapeutic temperature management products, are also scheduled. A listing and schedule of the presentations is available at www.zoll.com/aha-presentations. All presentations will be available from the AHA and ZOLL at the conclusion of the AHA Scientific Sessions program.

ZOLL's resuscitation and critical care products on display in Booth #1035 support the 2010 AHA Guidelines with their increased emphasis on high-quality CPR and post-resuscitation care. Featured in the exhibit are:

  • All ZOLL defibrillators, from ACLS to AEDs, which feature Real CPR Help audio and visual feedback for the correct depth and rate, and tracking of idle time.
  • The R Series® Code-Ready® family of defibrillators for hospitals, the E Series® defibrillators for EMS, and the AED Pro®, which all offer See-Thru CPR, a breakthrough technology that filters out CPR artifact from the ECG to reduce durations of CPR interruptions.
  • The AutoPulse, an automated, portable, chest compression device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during resuscitation. The AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion even when moving patients, traveling in an ambulance, or during a PCI procedure.
  • The LifeVest, for early intervention, worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient's physician time to assess his/her long-term arrhythmic risk and make appropriate plans.
  • Intravascular Temperature Management (IVTM), which offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients.
  • RescueNet® 12-Lead, an advanced and versatile system that allows health care providers to easily acquire and transmit ECG information from the field into the cath lab to assist clinicians in meeting standards for door-to-balloon times.
  • CodeNet®, the first software system that allows hospital teams to better document, manage, and review cardiac arrest event and resuscitation information.
  • PocketCPR® for the iPhone® and the Droid®, a training app to provide CPR training and practice using the AHA CPR Guidelines.

Source: ZOLL Medical Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy